Crohn's Outcomes — What We Measure and When We Judge It

We do not publish a success rate

We have no aggregate outcome figure we can substantiate with a sample size and a method, and until we do, we will not put a number on this page. A claim you can check is more credible than one you cannot.

The five markers we track

• Stool frequency and urgency
• Blood in stool
• Abdominal pain — severity and pattern
• Fatigue and energy
• Medication load — dose and frequency of steroids, biologics, immunomodulators

We deliberately do not lead on "feeling normal". It is the last thing to move, and judging progress by it is how patients abandon something that is working.

The objective markers — and they stay with your gastroenterologist

• Faecal calprotectin
• CRP
• Haemoglobin, ferritin, B12
• Albumin

These are your gastroenterologist's, and they remain so. We work alongside conventional monitoring and never ask you to stop it. It is how both of us find out, objectively, whether this is working.

When we judge it

• Weeks 1–4 — energy, sleep, digestion move first. Bowel symptoms often have not. Expected.
• Weeks 3–6 — the Partial Improvement Plateau. Not failure.
• Months 2–4 — this is when the disease should start to change.
• Months 4–8 — same triggers, diminished response.
• Month 8+ — stable remission is assessed. Not before.

Who responds well

Inflammatory (non-stricturing, non-penetrating) disease. Shorter duration. Preserved repair capacity. A clear driver profile. Patients who begin while still on their current medication.

Who this does not help — plainly

• Established fibrotic strictures. Scar does not reverse with any internal treatment.
• Extensive prior resection. Removed bowel does not grow back.
• Severe penetrating / fistulising disease — complex, and response varies widely.
• Anyone in an acute severe flare, with obstruction, or with signs of perforation. You need

emergency conventional care — now, not us, and not later.

For patients with advanced structural change the realistic goal is a lower inflammatory burden and a lower medication load — not remission. We would rather turn away a patient we cannot help than take their money.